Schedule 13D ownership disclosure
Perspective Therapeutics Inc
Common Stock, $0.001 par value · CUSIP: 46489V302
Event date: 2026-11-10
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- Lantheus Holdings, Inc.Reported CIK 0001521036
Shares: 4,739,011 · Class: 3.9%
- Lantheus Medical Imaging, Inc.
Shares: 4,739,011 · Class: 3.9%
- Lantheus Alpha Therapy, LLCReported CIK 0002010224
Shares: 4,739,011 · Class: 3.9%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0001193125-26-458595
- Form type
- SCHEDULE 13D/A
- Filer
- Lantheus Holdings, Inc.
- CIK
- CIK 1521036
- Filed
- Nov 12, 2026
- Reporting period
- Nov 10, 2026
- Description
- Schedule 13D beneficial ownership